Skip to main content

Advertisement

Table 1 ALK inhibitors discussed and their activity against various ALK resistance mutations

From: The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)

  Drug
ALK Resistance Mutations Crizontinib Ceritinib Alectinib Brigatinib Lorlatinib
L1196M  
G1269A  
S1206Y   
V1180L  
G1202R
C1156Y  
1151Tins   
F1174C/L  
L1152R/P ♦ (L1152R)   
L1198P    • (L1198F)  
I1171N/T • (I1171N)  
D1203N    
  1. ♦ Mutation confers resistance/insensitivity to the inhibitor
  2. • Inhibitor overcomes resistance mutation